In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Deals Research and Development Strategies

Evenity Gets CHMP Nod On Second Pass

UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.

Approvals Europe

First Ebola Vaccine Among Seven Products To Get EMA Nod

Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.

Approvals Europe

Top US FDA Officials Continue To Lament Advisory Cmte. Recruitment Difficulties

Strict conflict of interest rules have hampered the agency's ability to fill advisory committee vacancies.

Advisory Committees FDA
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register